Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
1.
Anticancer Res ; 44(3): 1219-1226, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-38423630

RESUMEN

BACKGROUND/AIM: Trifluridine/tipiracil (FTD/TPI) is used to treat metastatic colorectal cancer (mCRC). Since the standard regimen of FTD/TPI features a complex dosing schedule and frequently results in severe hematological toxicities, a simplified regimen has emerged, in which FTD/TPI is orally administered biweekly. However, the survival benefits and potential adverse events associated with the biweekly FTD/TPI regimen have not been fully evaluated in previous reports. Therefore, in this study, the differences in efficacy and safety between the standard and biweekly FTD/TPI regimens were retrospectively investigated in patients with mCRC. PATIENTS AND METHODS: Data from 90 patients who received FTD/TPI for mCRC were extracted from the electronic medical records at the Osaka University Hospital. According to the inclusion and exclusion criteria, 85 of the 90 patients were enrolled in the study. We compared patient characteristics, overall survival (OS), progression-free survival (PFS), and adverse events between the standard (n=56) and biweekly groups (n=29). RESULTS: The biweekly group exhibited prolonged OS and PFS compared to patients in the standard group. Multivariate analysis for OS and PFS demonstrated that the biweekly regimen was the only significant factor that affected OS, and not PFS (HR=0.561, p=0.049). Kaplan-Meier analysis indicated that neutropenia (grade ≥3) in the biweekly group was significantly prolonged compared to the standard group (p=0.012). However, there were no significant differences in adverse events between the two groups (p>0.999). CONCLUSION: The biweekly FTD/TPI regimen, compared to the standard regimen, should enhance both OS and PFS in patients with mCRC without escalating any adverse event.


Asunto(s)
Neoplasias del Colon , Neoplasias Colorrectales , Demencia Frontotemporal , Pirrolidinas , Neoplasias del Recto , Timina , Humanos , Uracilo/efectos adversos , Estudios Retrospectivos , Trifluridina/efectos adversos , Demencia Frontotemporal/inducido químicamente , Neoplasias Colorrectales/patología , Neoplasias del Colon/inducido químicamente , Combinación de Medicamentos , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos
2.
Yakugaku Zasshi ; 142(8): 905-909, 2022.
Artículo en Japonés | MEDLINE | ID: mdl-35908952

RESUMEN

The management of syncope is clinically important for heart failure (HF) patients. We herein describe a case on the efficacy of disopyramide for refractory syncope in HF with preserved ejection fraction (HFpEF). An 82-year-old man was hospitalized for respiratory distress and lower limb edema and was subsequently diagnosed with HFpEF. The use of diuretics improved HF symptoms; however, on day 10 after hospitalization, a rapid decrease in blood pressure and transient loss of consciousness developed. After neurologic examination, he was diagnosed with pure autonomic failure. Although he was administered midodrine 8 mg/d, fludrocortisone 0.1 mg/d, and droxidopa 300 mg/d, syncope was observed once a day on average. According to the Holter electrocardiogram, the patient's heart rate and coefficient of variation of R-R intervals (CVRR) during the day were unstable. In addition, high frequency power (parasympathetic nerve activity) was significantly higher than low frequency power (both sympathetic and parasympathetic nerves activity), suggesting that the parasympathetic nerves may have been highly active while the sympathetic nerves would have been blocked. On day 29, a pharmacist proposed disopyramide 300 mg/d, which blocks parasympathetic nerves and improves neural-mediated syncope, to the attending doctor. After the initiation of disopyramide, transient loss of consciousness was not observed. Furthermore, the diurnal variation in the heart rate and CVRR completely disappeared. In conclusion, disopyramide would be effective for refractory syncope in patients with HFpEF, and the Holter electrocardiogram may be a useful tool for the assessment of drug efficacy by pharmacists.


Asunto(s)
Disopiramida , Insuficiencia Cardíaca , Anciano de 80 o más Años , Electrocardiografía Ambulatoria/efectos adversos , Insuficiencia Cardíaca/complicaciones , Insuficiencia Cardíaca/tratamiento farmacológico , Humanos , Masculino , Volumen Sistólico , Síncope/tratamiento farmacológico , Síncope/etiología
3.
Anticancer Res ; 42(5): 2591-2598, 2022 May.
Artículo en Inglés | MEDLINE | ID: mdl-35489750

RESUMEN

BACKGROUND/AIM: Hand-foot syndrome (HFS) is the most common adverse event associated with capecitabine, and its pathogenesis is known to be associated with inflammation. Proton pump inhibitors (PPIs) reportedly exert anti-inflammatory effects; however, the impact of PPIs on capecitabine-induced HFS needs to be clarified in the clinical setting. In the present study, we retrospectively investigated the efficacy and safety of PPIs in patients with breast cancer receiving capecitabine. PATIENTS AND METHODS: We analyzed the effects of PPIs on the development of severe HFS (grade ≥2), progression-free survival (PFS), and overall survival (OS) in 195 patients who received capecitabine chemotherapy for breast cancer. RESULTS: In total, 50 patients (26%) were treated with PPIs, while 145 patients (74%) did not receive PPIs. The incidence of severe HFS was significantly lower in patients who received PPIs (18%) than in patients who did not receive PPIs (43%, p=0.001), and the discontinuation rate of capecitabine therapy due to HFS was also lower in patients receiving PPIs than in those who did not receive PPIs (p=0.003). Multivariate analysis revealed that concomitant PPIs use was an independent factor that significantly contributed to the prevention of severe HFS (odds ratio (OR)=0.265, p=0.003). Meanwhile, no significant difference in median PFS and OS values was observed between patients treated with and without PPIs. CONCLUSION: Concomitant use of PPIs could ameliorate capecitabine-induced HFS in patients with breast cancer.


Asunto(s)
Neoplasias de la Mama , Síndrome Mano-Pie , Neoplasias de la Mama/patología , Capecitabina/efectos adversos , Femenino , Síndrome Mano-Pie/tratamiento farmacológico , Síndrome Mano-Pie/etiología , Humanos , Inhibidores de la Bomba de Protones/efectos adversos , Estudios Retrospectivos
4.
Int Heart J ; 62(6): 1297-1304, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34853223

RESUMEN

Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) frequently induce cardiovascular adverse events, though VEGFR-TKIs contribute to the improvement of the prognosis of patients with malignancies. It is widely accepted that VEGFR-TKIs impair left ventricular systolic functions; however, their effects on diastolic functions remain to be fully elucidated. The purpose of this study was to analyze the impact of VEGFR-TKIs on left ventricular diastolic functions. This study was designed as a retrospective single-center cohort study in Japan. We assessed 24 cases who received VEGFR-TKI monotherapy (sunitinib, sorafenib, pazopanib, axitinib) with left ventricular ejection fraction (LVEF) above 50% during the therapy at the Osaka University Hospital from January 2008 to June 2019. Left ventricular diastolic functions were evaluated by the change in echocardiographic parameters before and after the VEGFR-TKI treatment. Both septal e' and lateral e's decreased after treatment (septal e': before, 6.1 ± 1.8; after, 5.0 ± 1.9; n = 21, P < 0.01; lateral e': before, 8.7 ± 2.8; after, 6.9 ± 2.3; n = 21, P < 0.01). E/A declined after VEGFR-TKIs administration, though not statistically significantly. In 20 cases with at least one risk factor for heart failure with preserved ejection fraction (HFpEF), E/A significantly decreased (0.87 ± 0.34 versus 0.68 ± 0.14; P < 0.05) as well as the septal and lateral e's. These results suggest that treatment with VEGFR-TKIs impairs left ventricular diastolic functions in patients with preserved LVEF, especially in those with risk factors for HFpEF.


Asunto(s)
Diástole/efectos de los fármacos , Inhibidores de Proteínas Quinasas/efectos adversos , Disfunción Ventricular Izquierda/inducido químicamente , Anciano , Estudios de Cohortes , Ecocardiografía , Femenino , Humanos , Masculino , Neoplasias/tratamiento farmacológico , Receptores de Factores de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Estudios Retrospectivos , Volumen Sistólico
5.
Bioorg Med Chem Lett ; 52: 128384, 2021 11 15.
Artículo en Inglés | MEDLINE | ID: mdl-34587541

RESUMEN

In previous work, we discovered a lead compound and conducted initial SAR studies on a novel series of dioxotriazines to identify the compound as one of the P2X3 receptor antagonists. This compound showed high P2X3 receptor selectivity and a strong analgesic effect. Although not selected for clinical development, the compound was evaluated from various aspects as a tool compound. In the course of the following study, the molecular structures of the dioxotriazines were modified based on pharmacokinetic/pharmacodynamic (PK/PD) analyses. As a result of these SAR studies, Sivopixant (S-600918) was identified as a clinical candidate with potent and selective antagonistic activity (P2X3 IC50, 4.2 nM; P2X2/3 IC50, 1100 nM) and a strong analgesic effect in the rat partial sciatic nerve ligation model (Seltzer model) of allodynia (ED50, 0.4 mg/kg).


Asunto(s)
Compuestos de Anilina/farmacología , Descubrimiento de Drogas , Antagonistas del Receptor Purinérgico P2X/farmacología , Piridinas/farmacología , Receptores Purinérgicos P2X3/metabolismo , Triazinas/farmacología , Compuestos de Anilina/síntesis química , Compuestos de Anilina/química , Relación Dosis-Respuesta a Droga , Estructura Molecular , Antagonistas del Receptor Purinérgico P2X/síntesis química , Antagonistas del Receptor Purinérgico P2X/química , Piridinas/síntesis química , Piridinas/química , Relación Estructura-Actividad , Triazinas/síntesis química , Triazinas/química
6.
Sci Rep ; 10(1): 4748, 2020 03 16.
Artículo en Inglés | MEDLINE | ID: mdl-32179851

RESUMEN

In non-small-cell lung cancer, mutation of epidermal growth factor receptor (EGFR) stimulates cell proliferation and survival. EGFR tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib are used as first-line therapy with drastic and immediate effectiveness. However, the disease eventually progresses in most cases within a few years due to the development of drug resistance. Here, we explored the role of progesterone membrane component 1 (PGRMC1) in acquired resistance to erlotinib and addressed the molecular mechanism of EGFR-TKI resistance induced by PGRMC1. The erlotinib-sensitive cell line PC9 (derived from non-small-cell lung cancer) and the erlotinib-resistant cell line PC9/ER were used. In proteomic and immunoblotting analyses, the PGRMC1 level was higher in PC9/ER cells than in PC9 cells. WST-8 assay revealed that inhibition of PGRMC1 by siRNA or AG-205, which alters the spectroscopic properties of the PGRMC1-heme complex, in PC9/ER cells increased the sensitivity to erlotinib, and overexpression of PGRMC1 in PC9 cells reduced their susceptibility to erlotinib. In the presence of erlotinib, immunoprecipitation assay showed that AG-205 suppressed the interaction between EGFR and PGRMC1 in PC9/ER cells. AG-205 decreased the expression of ß-catenin, accompanied by up-regulation of IκBα (also known as NFKBIA). Furthermore, AG-205 reduced the expression of ß-TrCP (also known as BTRC), suggesting that PGRMC1 enhanced the crosstalk between NF-κB (also known as NFKB) signaling and Wnt/ß-catenin signaling in an erlotinib-dependent manner. Finally, treatment with the Wnt/ß-catenin inhibitor XAV939 enhanced the sensitivity of PC9/ER cells to erlotinib. These results suggest that PGRMC1 conferred resistance to erlotinib through binding with EGFR in PC9/ER cells, initiating crosstalk between the Wnt/ß-catenin and NF-κB pathways.


Asunto(s)
Adenocarcinoma/genética , Adenocarcinoma/patología , Antineoplásicos , Resistencia a Antineoplásicos/genética , Clorhidrato de Erlotinib/farmacología , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/patología , Proteínas de la Membrana/metabolismo , FN-kappa B/metabolismo , Inhibidores de Proteínas Quinasas , Receptores de Progesterona/metabolismo , Transducción de Señal/genética , Proteínas Wnt/metabolismo , Vía de Señalización Wnt/genética , beta Catenina/metabolismo , Adenocarcinoma/metabolismo , Línea Celular Tumoral , Receptores ErbB/metabolismo , Humanos , Neoplasias Pulmonares/metabolismo
7.
Oncotarget ; 9(101): 37520-37533, 2018 Dec 25.
Artículo en Inglés | MEDLINE | ID: mdl-30680067

RESUMEN

The acquisition of resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) is one of the major problems in the pharmacotherapy against non-small cell lung cancers; however, molecular mechanisms remain to be fully elucidated. Here, using a newly-established erlotinib-resistant cell line, PC9/ER, from PC9 lung cancer cells, we demonstrated that the expression of translation-related molecules, including eukaryotic translation initiation factor 3 subunit C (eIF3c), was upregulated in PC9/ER cells by proteome analyses. Immunoblot analyses confirmed that eIF3c protein increased in PC9/ER cells, compared with PC9 cells. Importantly, the knockdown of eIF3c with its siRNAs enhanced the drug sensitivity in PC9/ER cells. Mechanistically, we found that LC3B-II was upregulated in PC9/ER cells, while downregulated by the knockdown of eIF3c. Consistently, the overexpression of eIF3c increased the number of autophagosomes, proposing the causality between eIF3c expression and autophagy. Moreover, chloroquine, an autophagy inhibitor, restored the sensitivity to erlotinib. Finally, immunohistochemical analyses of biopsy samples showed that the frequency of eIF3c-positive cases was higher in the patients with EGFR-TKI resistance than those prior to EGFR-TKI treatment. Moreover, the eIF3c-positive cases exhibited poor prognosis in EGFR-TKI treatment. Collectively, the upregulation of eIF3c could impair the sensitivity to EGFR-TKI as a novel mechanism of the drug resistance.

8.
Clin Exp Pharmacol Physiol ; 42(3): 278-86, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25482107

RESUMEN

Excitation of the renal sympathetic nervous system is important for the development of ischaemic acute kidney injury (AKI) in rats. We reported that intravenous treatment with GABA has preventive effects against ischaemia/reperfusion (I/R)-induced renal dysfunction with histological damage in rats; however, the mechanisms underlying these effects on renal injury remain unknown. Thus, the aim of the present study was to clarify how GABA mechanistically affects ischaemic AKI in rats. Ischaemic AKI was induced in rats by clamping the left renal artery and vein for 45 min and then reperfusing the kidney to produce I/R-induced injury. Treatment with the GABAB receptor antagonist CGP52432 (100 nmol/kg, i.v., or 1 nmol/kg, i.c.v.) abolished the suppressive effects of 50 µmol/kg, i.v., GABA on enhanced renal sympathetic nerve activity (RSNA) during ischaemia, leading to elimination of the renoprotective effects of GABA. Intracerebroventricular treatment with 0.5 µmol/kg GABA or i.v. treatment with 1 µmol/kg baclofen, a selective GABAB receptor agonist, prevented the I/R-induced renal injury equivalent to i.v. treatment with GABA. Conversely, i.v. treatment with 10 µmol/kg bicuculline, a GABAA receptor antagonist, failed to affect the preventive effects of GABA against ischaemic AKI. We therefore concluded that GABAB receptor stimulation in the central nervous system, rather than peripheral GABAB receptor stimulation, mediates the preventive effect of GABA against ischaemic AKI by suppressing the enhanced RSNA induced by renal ischaemia.


Asunto(s)
Lesión Renal Aguda/prevención & control , Citoprotección/efectos de los fármacos , Riñón/efectos de los fármacos , Daño por Reperfusión/prevención & control , Ácido gamma-Aminobutírico/farmacología , Lesión Renal Aguda/metabolismo , Lesión Renal Aguda/patología , Animales , Bencilaminas/farmacología , Bicuculina/farmacología , Antagonistas de Receptores de GABA-A/farmacología , Riñón/patología , Masculino , Ácidos Fosfínicos/farmacología , Ratas , Receptores de GABA-A/metabolismo , Daño por Reperfusión/metabolismo , Daño por Reperfusión/patología
9.
BMC Endocr Disord ; 14: 96, 2014 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-25511531

RESUMEN

BACKGROUND: Insulin resistance is one of the hallmark manifestations of obesity and Type II diabetes and reversal of this pathogenic abnormality is an attractive target for new therapies for Type II diabetes. A recent report that metformin, a drug known to reverse insulin resistance, demonstrated in vitro the metformin can inhibit AMP deaminase (AMPD) activity. Skeletal muscle is one of the primary organs contributing to insulin resistance and that the AMPD1 gene is selectively expressed at high levels in skeletal muscle. METHODS: Recognizing the background above, we asked if genetic disruption of the AMPD1 gene might ameliorate the manifestations of insulin resistance. AMPD1 deficient homozygous mice and control mice fed normal chow diet or a high-fat diet, and blood analysis, glucose tolerance test and insulin tolerance test were performed. Also, skeletal muscle metabolism and gene expression including nucleotide levels and activation of AMP activated protein kinase (AMP kinase) were evaluated in both conditions. RESULTS: Disruption of the AMPD1 gene leads to a less severe state of insulin resistance, improved glucose tolerance and enhanced insulin clearance in mice fed a high fat diet. Given the central role of AMP kinase in insulin action, and its response to changes in AMP concentrations in the cell, we examined the skeletal muscle of the AMPD1 deficient mice and found that they have greater AMP kinase activity as evidenced by higher levels of phosphorylated AMP kinase. CONCLUSIONS: Taken together these data suggest that AMPD may be a new drug target for the reversal of insulin resistance and the treatment of Type II diabetes.


Asunto(s)
AMP Desaminasa/genética , AMP Desaminasa/metabolismo , Proteínas Quinasas Activadas por AMP/metabolismo , Diabetes Mellitus Tipo 2/metabolismo , Resistencia a la Insulina , Músculo Esquelético/metabolismo , Obesidad/metabolismo , Proteínas Quinasas Activadas por AMP/efectos de los fármacos , Animales , Glucemia/metabolismo , Diabetes Mellitus Tipo 2/etiología , Dieta Alta en Grasa , Modelos Animales de Enfermedad , Regulación de la Expresión Génica , Resistencia a la Insulina/genética , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Músculo Esquelético/efectos de los fármacos , Obesidad/etiología
10.
J Med Chem ; 57(15): 6781-94, 2014 Aug 14.
Artículo en Inglés | MEDLINE | ID: mdl-25057800

RESUMEN

A series of novel tetrahydropyridinecarboxamide TRPV1 antagonists were prepared and evaluated in an effort to optimize properties of previously described lead compounds from piperazinecarboxamide series. The compounds were evaluated for their ability to block capsaicin and acid-induced calcium influx in CHO cells expressing human TRPV1. The most potent of these TRPV1 antagonists were further characterized in pharmacokinetic, efficacy, and body temperature studies. On the basis of its pharmacokinetic, in vivo efficacy, safety, and toxicological properties, compound 37 was selected for further evaluation in human clinical trials.


Asunto(s)
Aminopiridinas/química , Analgésicos/química , Dolor/tratamiento farmacológico , Canales Catiónicos TRPV/antagonistas & inhibidores , Aminopiridinas/farmacocinética , Aminopiridinas/farmacología , Analgésicos/farmacocinética , Analgésicos/farmacología , Animales , Temperatura Corporal/efectos de los fármacos , Células CHO , Calcio/metabolismo , Capsaicina/farmacología , Cricetulus , Adyuvante de Freund , Ganglios Espinales/citología , Humanos , Concentración de Iones de Hidrógeno , Masculino , Dolor/etiología , Ratas Sprague-Dawley , Células Receptoras Sensoriales/efectos de los fármacos , Células Receptoras Sensoriales/fisiología , Estereoisomerismo , Relación Estructura-Actividad
11.
Mol Genet Metab Rep ; 1: 51-59, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-27896074

RESUMEN

Mutation of the AMP deaminase 1 (AMPD1) gene, the predominate AMPD gene expressed in skeletal muscle, is one of the most common inherited defects in the Caucasian population; 2-3% of individuals in this ethnic group are homozygous for defects in the AMPD1 gene. Several studies of human subjects have reported variable results with some studies suggesting this gene defect may cause symptoms of a metabolic myopathy and/or easy fatigability while others indicate individuals with this inherited defect are completely asymptomatic. Because of confounding problems in assessing muscle symptoms and performance in human subjects with different genetic backgrounds and different environmental experiences such as prior exercise conditioning and diet, a strain of inbred mice with selective disruption of the AMPD1 was developed to study the consequences of muscle AMPD deficiency in isolation. Studies reported here demonstrate that these animals are a good metabolic phenocopy of human AMPD1 deficiency but they exhibit no abnormalities in muscle performance in three different exercise protocols.

12.
J Pharmacol Exp Ther ; 338(3): 767-74, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21632868

RESUMEN

The excitation of the renal sympathetic nervous system plays an important role in the development of ischemic acute kidney injury (AKI) in rats. We have reported that intravenous treatment with GABA has preventive effects on ischemia/reperfusion (I/R)-induced renal dysfunction with histological damage in rats. However, detailed mechanisms of the action of GABA on the renal injury were still unknown. Therefore, in the present study, we aimed to clarify the detailed mechanisms of GABA in ischemic AKI in rats. Ischemic AKI was induced by clamping the left renal artery and vein for 45 min. Thereafter, the kidney was reperfused to produce I/R-induced injury. Intravenous or intracerebroventricular treatment with 3-[[[(3,4-dichlorophenyl)methyl]amino]propyl] diethoxymethyl) phosphinic acid (CGP52432), a GABA(B) receptor antagonist, abolished the suppressive effects of intravenously applied GABA on enhanced renal sympathetic nerve activity during ischemia, leading to the elimination of the renoprotective effects of GABA. Intracerebroventricular treatment with GABA or intravenous treatment with baclofen, a selective GABA(B) receptor agonist, prevented I/R-induced renal injury equivalent to intravenous treatment with GABA. However, intravenous treatment with bicuculline, a GABA(A) receptor antagonist, failed to affect the preventive effects of GABA on ischemic AKI. Therefore, we demonstrated the novel finding that the preventive effect of GABA on ischemic AKI through the suppression of enhanced renal sympathetic nerve activity induced by renal ischemia is presumably mediated via GABA(B) receptor stimulation in the central nervous system rather than peripheral GABA(B) receptor.


Asunto(s)
Lesión Renal Aguda/prevención & control , Daño por Reperfusión/prevención & control , Ácido gamma-Aminobutírico/farmacología , Lesión Renal Aguda/patología , Animales , Baclofeno/farmacología , Bencilaminas/farmacología , Bicuculina/farmacología , Nitrógeno de la Urea Sanguínea , Agonistas del GABA/farmacología , Antagonistas del GABA/farmacología , Inyecciones Intravenosas , Inyecciones Intraventriculares , Riñón/efectos de los fármacos , Riñón/inervación , Riñón/patología , Pruebas de Función Renal , Masculino , Ácidos Fosfínicos/farmacología , Ratas , Ratas Sprague-Dawley , Receptores de GABA-A/efectos de los fármacos , Receptores de GABA-B/efectos de los fármacos , Sistema Nervioso Simpático/efectos de los fármacos , Ácido gamma-Aminobutírico/administración & dosificación
13.
Eur J Pharmacol ; 623(1-3): 113-8, 2009 Nov 25.
Artículo en Inglés | MEDLINE | ID: mdl-19765583

RESUMEN

Enhanced renal sympathetic nerve activity during ischemic period and the renal venous norepinephrine overflow after reperfusion play important roles in the development of ischemic acute kidney injury. We investigated the effect of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter mainly in the central nervous system, on ischemia/reperfusion-induced acute kidney injury in anesthetized rats. Ischemic acute kidney injury was induced by clamping the left renal artery and vein for 45min followed by reperfusion 2weeks after the contralateral nephrectomy. Intravenous injection of GABA (10 and 50micromol/kg) to ischemic acute kidney injury rats dose-dependently suppressed the enhanced renal sympathetic nerve activity during the renal ischemia, the renal venous norepinephrine overflow after reperfusion and attenuated the ischemia/reperfusion-induced renal dysfunction with histological damage. Intravenous injection of CGP52432 (0.1micromol/kg), a selective GABA(B) receptor antagonist, eliminated the preventive effect by GABA (50micromol/kg) on ischemic acute kidney injury. In contrast, intravenous injection of baclofen (1micromol/kg), a selective GABA(B) receptor agonist, attenuated the ischemia/reperfusion-induced renal injury equivalent to GABA (50micromol/kg). These results indicate that GABA prevents the development of ischemia/reperfusion-induced acute kidney injury presumably via GABA(B) receptor, by suppressing the enhanced renal sympathetic nerve activity during ischemia and the increased norepinephrine overflow from renal sympathetic nerve ending.


Asunto(s)
Enfermedades Renales/prevención & control , Riñón/fisiopatología , Daño por Reperfusión/prevención & control , Ácido gamma-Aminobutírico/metabolismo , Animales , Baclofeno/farmacología , Bencilaminas/farmacología , Agonistas del GABA/farmacología , Antagonistas del GABA/farmacología , Antagonistas de Receptores de GABA-B , Riñón/irrigación sanguínea , Riñón/inervación , Riñón/patología , Enfermedades Renales/patología , Enfermedades Renales/fisiopatología , Pruebas de Función Renal , Necrosis Tubular Aguda/patología , Necrosis Tubular Aguda/prevención & control , Masculino , Neuronas/fisiología , Norepinefrina/sangre , Ácidos Fosfínicos/farmacología , Ratas , Ratas Sprague-Dawley , Daño por Reperfusión/fisiopatología , Sistema Nervioso Simpático/fisiopatología , Factores de Tiempo , Ácido gamma-Aminobutírico/administración & dosificación
14.
Bioorg Med Chem Lett ; 14(15): 4013-7, 2004 Aug 02.
Artículo en Inglés | MEDLINE | ID: mdl-15225717

RESUMEN

A series of 2-amino-3-cyano-4-alkyl-6-(2-hydroxyphenyl)pyridine derivatives was synthesized and evaluated as IkappaB kinase beta (IKK-beta) inhibitors. Substitution of an aminoalkyl group for the aromatic group at the 4-position on the core pyridine ring resulted in a marked increase in both kinase enzyme and cellular potencies, and provided potent IKK-beta inhibitors with IC(50) values of below 100 nM.


Asunto(s)
Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/farmacología , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Inhibidores Enzimáticos/química , Humanos , Quinasa I-kappa B , Cinética , Modelos Moleculares , Conformación Molecular , Proteínas Recombinantes/antagonistas & inhibidores , Relación Estructura-Actividad
15.
Bioorg Med Chem Lett ; 14(15): 4019-22, 2004 Aug 02.
Artículo en Inglés | MEDLINE | ID: mdl-15225718

RESUMEN

A series of 2-amino-3-cyano-4-alkyl-6-(2-hydroxyphenyl)pyridine derivatives was synthesized and evaluated as I kappaB kinase beta (IKK-beta) inhibitors. Modification of a novel IKK-beta inhibitor 1 (IKK-beta IC(50)=1500 nM, Cell IC(50)=8000 nM) at the 4-phenyl ring and 6-phenol group on the pyridine core ring resulted in a marked increased in biological activities. An optimized compound, 2-amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-4-piperidin-4-yl nicotinonitrile, exhibited excellent in vitro profiles (IKK-beta IC(50)=8.5 nM, Cell IC(50)=60 nM) and a strong oral efficacy in in vivo anti-inflammatory assays (significant effects at 1mg/kg, po in arachidonic acid-induced ear edema model in mice).


Asunto(s)
Antiinflamatorios/síntesis química , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Piridinas/farmacología , Animales , Antiinflamatorios/farmacología , Modelos Animales de Enfermedad , Edema/prevención & control , Humanos , Quinasa I-kappa B , Cinética , Ratones , Modelos Moleculares , Estructura Molecular , Piridinas/síntesis química , Proteínas Recombinantes/antagonistas & inhibidores , Relación Estructura-Actividad
16.
J Org Chem ; 69(3): 785-9, 2004 Feb 06.
Artículo en Inglés | MEDLINE | ID: mdl-14750805

RESUMEN

The additive effect on the diastereoselective [2 + 2] photocycloaddition of chiral cyclohexenones 1 to ethylene is examined. A novel and fairly efficient method of increasing the diastereoselectivity in the reaction of 1a was elucidated. The de value increased from 56% to 83% by the addition of 1-phenylnaphthalene. The major product 2a was isolated by the recrystallization of the diastereomeric mixture (major/minor = 11/1), of which X-ray analysis confirmed the absolute configuration of the bicyclic system of 2a. Hydrolysis for removing the chiral auxiliary and subsequent esterification afforded the optically pure bicyclo[4.2.0]octanone derivative 5. From the fluorescence spectral analyses and other experimental results, the additive effect is attributed to the complex formation of chiral cyclohexenone 1a and added naphthalenes.

17.
Bioorg Med Chem Lett ; 13(5): 913-8, 2003 Mar 10.
Artículo en Inglés | MEDLINE | ID: mdl-12617920

RESUMEN

IkappaB kinase beta (IKK-beta) is a serine-threonine protein kinase critically involved in the activation of the transcription factor Nuclear Factor kappa B (NF-kappaB) in response to various inflammatory stimuli. We have identified a small molecule inhibitor of IKK-beta. Optimization of the lead compound resulted in improvements in both in vitro and in vivo potency, and provided IKK-beta inhibitors exhibiting potent activity in an acute cytokine release model (LPS-induced TNFalpha).


Asunto(s)
Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Animales , Línea Celular , Quimiocina CCL5/análisis , Humanos , Quinasa I-kappa B , Concentración 50 Inhibidora , Ratones , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Recombinantes/antagonistas & inhibidores , Proteínas Recombinantes/metabolismo , Relación Estructura-Actividad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA